NIR Diagnostics completes internal testing of OmegaNIR(TM)



    - Device monitors omega-6 and omega-3 levels non-invasively -

    TSX Venture: NID

    CAMPBELLVILLE, ON, June 4 /CNW/ - NIR Diagnostics Inc. (TSX Venture:
NID), an innovator in the development of in-vitro and in-vivo medical
diagnostic devices today announced that it has successfully completed internal
testing of its in-vivo light-based platform for an application that monitors
levels of omega-6 and omega-3 fatty acids non-invasively. The portable
OmegaNIR(TM) device has been developed on the Company's VisionNIR(TM) platform
which allows a user to monitor blood and tissue with the use of near-infrared
light. This eliminates the need to secure a blood sample for expensive and
time consuming laboratory tests. NIR Diagnostics plans to initiate live
patient testing of cardiac patients at cardiac clinics in Los Angeles County,
California.
    "OmegaNIR(TM) features a capability that is consistent with our corporate
vision of developing technologies that improve the way health care
professionals manage disease and ultimately alter the way individuals manage
their personal health," commented Duncan J. MacIntyre, President, CEO and
Executive Vice Chairman. "We will continue to evaluate, and as appropriate,
add new blood analytes to our VisionNIR(TM) non-invasive platform to improve
individual health."
    OmegaNIR(TM) measures the omega-6 and omega-3 blood levels on a ratio
basis. The ratio of an individual's omega-6 to omega-3 levels is recognized by
the American Heart Association as influencing blood pressure, triglyceride
levels, growth rate of atherosclerotic plaques, incidence of cardiac
arrhythmias, myocardial infarctions and stroke. In addition, the U.S. Food and
Drug Administration have also stated that "supportive but not conclusive
research shows that consumption of EPA and DHA (n-3) fatty acids may reduce
the risk of coronary heart disease." According to the American Heart
Association the ideal omega-6 to omega-3 ratio is 1:1. Dietary choices and
behavioral lifestyles are contributing factors in the actual omega-6 to
omega-3 ratios reaching as high as 20:1 for some individuals. This may result
in the increase in diseases with an inflammatory component such as coronary
artery disease, asthma, autoimmunity and neurodegenerative diseases.
Researchers are also working to determine the impact of omega levels and
omega-6, omega-3 imbalance on other chronic diseases, like diabetes.
    "Many patients suffering from cardiac disease are now prescribed omega-6
fatty acids to aid in blood circulation, but the actual impact of prescribed
dosages is not evaluated due to the expense and time associated with testing
omega-6 and omega-3 levels in a laboratory setting," said Dr. Fred Dennis,
California based Medical Director of NIR Diagnostics. "We expect to initiate
live patient testing of cardiac patients shortly. The data derived from this
study, in addition to other planned studies conducted by, and on behalf of NIR
Diagnostics, will form part of the regulatory dossier for a proposed
OmegaNIR(TM) regulatory submission."
    The study is designed to facilitate an improved understanding of the
correlation between the ratio of omega-6 and omega-3 and cardiac disease. NIR
Diagnostics intends to initiate the study after receiving the appropriate IRB
approval which is anticipated in June 2008. NIR Diagnostics intends to pursue
potential distributors for the OmegaNIR(TM) device for sales outside of the
global multi-level marketing nutrition market.
    OmegaNIR(TM) takes only seconds to measure an individual's omega levels.
Internal testing has been completed on male and female patients across a broad
range of race and age categories. NIR Diagnostics' patented technology emits
light from a small light bulb and then measures the absorbance of light within
the finger via a complex detector system. OmegaNIR(TM) was developed and
designed exclusively by NIR Diagnostics, using the company's VisionNIR(TM)
non-invasive platform, a technology capable of monitoring multiple analytes at
the same time from the same scan. The VisionNIR(TM) platform device will be on
exhibit at the Company's upcoming Annual Meeting of Shareholders on June 19th,
2008 in Toronto.

    About Omega-6 and Omega-3

    Omega-6 and omega-3 contain essential fatty acids necessary for good
health which the body cannot manufacture on its own and therefore must be
consumed as part of a balanced diet. Omega-6 and omega-3 compete for the same
metabolic enzymes which impact downstream hormone levels and consequently the
body's metabolic function. The ratio of omega-6 to omega-3 is an element of
good health.

    About NIR Diagnostics

    NIR Diagnostics is an innovator in the development of near-infrared,
spectroscopic medical diagnostics. The Company has an extensive portfolio of
optical, electronic and algorithm related patents in the field of in-vitro and
in-vivo blood analysis.

    Forward-looking Statements

    This press release contains information that is forward-looking
information within the meaning of applicable securities laws. In some cases,
forward-looking information can be identified by the use of terms such as
"may", "will", "should", "expect", "plan", "anticipate", "believe", "intend",
"estimate", "predict", "potential", "continue" or the negative of these terms
or other similar expressions concerning matters that are not historical facts.
Particularly, statements about the planned development of diagnostic devices,
the potential efficacy of such devices, the expected timing of product sales
and the sufficiency of funds available to finance ongoing operations are
forward-looking information.
    Forward-looking information, by its nature necessarily involves risks and
uncertainties including, without limitation, the difficulty of predicting
regulatory approvals, market acceptance and demand for new products, the
protection of intellectual property connected with devices, the impact of
competitive products, and other similar or related risks and uncertainties.
Additional risks and uncertainties affecting the Company are discussed in the
Risks and Uncertainties section of the MD&A for the year ended December 31,
2007 available on SEDAR at www.sedar.com. If any of these risks or
uncertainties were to materialize or if the factors and assumptions underlying
the forward-looking information were to prove incorrect, actual results could
vary materially from those that are expressed or implied by the
forward-looking information contained herein. The Company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.





For further information:

For further information: Duncan MacIntyre, President, CEO and Executive
Vice Chairman, NIR Diagnostics Inc., (905) 854-5727, (905) 854-5729 Fax,
E-mail: info@nirdiagnostics.com, Internet: www.nirdiagnostics.com; Ross
Marshall, Investor Relations, (416) 815-0700 ext. 238, (416) 815-0080 Fax,
E-mail: rmarshall@equicomgroup.com, Internet: www.equicomgroup.com

Organization Profile

NIR DIAGNOSTICS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890